kag, read the white paper again that BOCX published in response to the SEC's questioning of their (lung cancer?) data. the paper discusses the cutoff values they use for specificity. while it would be great for the "personalizaton" application if individuals had constant levels of RECAF, it has no bearing on whether or not RECAF will work as a general diagnostic tool. this is because there are clearly levels of RECAF which are abnormal across all individuals (thus the specificity cutoff points).
News 
Market Data 
Discover 
